HOME >> BIOLOGY >> NEWS
Eastern Europe urged to prepare now for growing threat of HIV resistance

Eastern Europe is warned to prepare for HIV drug resistance, a problem that is now being witnessed in patients in Poland after only five years of HIV treatment being available. Experts at an HIV congress in Warsaw heard today that FUZEON (enfuvirtide, formerly known as T-20), the latest weapon in the fight against HIV drug resistance, is a valuable tool to both patients and payers in the treatment of HIV, particularly when used earlier in pre-treated patients.

Eastern Europe urged to prepare for HIV resistance

John Bowis, OBE, Member of the European Parliament applauds the Ministry of Health in Poland for taking a pro-active lead in the fight against HIV and drug resistance: "The growing problem of HIV resistance is a serious issue which all members of the EU have a responsibility to manage. We must commit to share knowledge, particularly those countries more experienced in tackling the HIV epidemic, in an effort to provide a consistent standard of care and avert a potential healthcare crisis. We need to ensure that all European countries are benefiting from new treatments and are allocating vital resources where they will be of most value."

The increasing prevalence of HIV drug resistance means that many patients can no longer benefit from the first three classes of HIV drugs. Unlike existing anti-HIV drugs, which act inside the cell once it has been infected, FUZEON works on the outside actively blocking the fusion of the virus with cells of the human immune system (CD4 cells). Because of this very different mechanism of action, FUZEON is active against HIV strains that have become resistant to current therapies. FUZEON reduces HIV levels and increases CD4 cell counts even in patients with resistance to the three conventional classes of HIV drugs.

Improving survival in pre-treated patients carrying drug-resistant HIV

Reduction in HIV levels and improvements in CD4 cell counts have been shown to result in improved s
'"/>

Contact: Alexander Watson
Alexander.watson@ketchum.com
44-771-267-5990
Ketchum
27-Oct-2003


Page: 1 2 3

Related biology news :

1. Eastern lowland gorilla population plummets 70 percent since 1994
2. Eastern U.S. benefits from emissions trading by power plants
3. Environment in Eastern Europe benefits from Swedish funding
4. USGS Finds That Mysterious Arkansas Bald Eagle Disease Has Spread To Ducks In Eastern States
5. Clean Air Act Reduces Acid Rain In Eastern U.S.
6. Even Moderate Air Pollution Reaching Eastern Wilderness Decreases Mountain Hikers Lung Function
7. European common frog found to use novel mating strategy
8. Zoonotic diseases - European scientists unite to fight diseases
9. Second call for proposals for the European Young Investigator Award
10. Common call for action on European Research Council (ERC)
11. EURYI Award given for the first time to 25 young European researchers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
Cached News: